This inventor holds 1 USPTO granted patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Camelia Dumitrescu: Innovator in Pulmonary Arterial Hypertension Treatment
Introduction
Camelia Dumitrescu is a notable inventor based in San Francisco, CA, who has made significant contributions to the field of medicine. She is particularly recognized for her work in transitioning patients treated for pulmonary arterial hypertension to selexipag. Her innovative approach aims to improve patient outcomes and enhance treatment efficacy.
Latest Patents
Camelia holds a patent titled "Transitioning patients treated for pulmonary arterial hypertension to selexipag." This patent outlines methods for transitioning patients from a non-selexipag prostacyclin pathway agent to selexipag, providing a new avenue for managing this challenging condition. She has 1 patent to her name, showcasing her commitment to advancing medical treatments.
Career Highlights
Camelia is currently employed at Actelion Pharmaceuticals Ltd., a company known for its focus on innovative therapies for pulmonary arterial hypertension and other serious conditions. Her role at Actelion allows her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Camelia has worked alongside esteemed colleagues such as Gary Arnold Palmer and Wade Benton. Their combined expertise fosters a collaborative environment that drives innovation and enhances the development of effective treatments.
Conclusion
Camelia Dumitrescu's work in the field of pulmonary arterial hypertension exemplifies the impact of innovation in medicine. Her dedication to improving patient care through her patented methods highlights the importance of research and collaboration in advancing healthcare solutions.